Pulmonary veno-occlusive disease in myeloproliferative disorder

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 213-216

  Willems, E ^a   Canivet, J L ^a,b   Ghaye, B ^a   De Leval, L ^a   Radermecker, M ^a   Preiser, J C ^a   Beguin, Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b University Hospital Centre   (Belgium)

Author keywords

Anagrelide; Chronic myeloproliferative disorder; Defibrotide; Pulmonary hypertension; Pulmonary veno occlusive disease

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; DEFIBROTIDE; ENOXAPARIN; FIBRINOLYTIC AGENT; HEMOSIDERIN; HYDROXYUREA; METHYLPREDNISOLONE; NITRIC OXIDE; OXYGEN;

AGED; ARTICLE; CASE REPORT; CAUSE OF DEATH; CHRONIC DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART OUTPUT; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; LUNG BIOPSY; LUNG EDEMA; LUNG FIBROSIS; LUNG INTERSTITIUM; LUNG LAVAGE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RELAPSE; RESPIRATORY FAILURE; SYSTOLIC DYSFUNCTION; THORAX RADIOGRAPHY; THROMBOCYTHEMIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VASCULAR RESISTANCE;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYDEOXYRIBONUCLEOTIDES; PULMONARY VENO-OCCLUSIVE DISEASE;

EID: 58849159140     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00157707     Document Type: Article

References (11)

1. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
2. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671-1679.
3. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.
4. Reisner SA, Rinkevich D, Markiewicz W, Tatarsky I, Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992; 93: 498-504.
5. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997; 23: 379-383.
6. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
7. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003; 17: 63-70.
8. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
9. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41: 229-237.
10. Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17: 1636-1642.
11. Pescador R, Porta R, Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost 1996; 22: 71-75.